Physician profile
Brandy L Deckard
NPI 1538367008
$963.85
in general payments reported to CMS, 2019-2025
15 companies · $84.52 in 2025
The $84.52 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $14.27 · 2021: $41.80 · 2022: $173 · 2023: $90.16 · 2024: $254 · 2025: $84.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $215 · Entertainment: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $215.07 |
| Entertainment | $213.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $241.71 | 2021-2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Alcon Vision LLC | $180.01 | 2019-2024 | Rocklatan |
| Shire North American Group INC | $116.48 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.22 | 2019 | |
| Bausch & Lomb Americas INC. | $60.85 | 2023-2025 | Infuse, Vyzulta |
| Novartis Pharmaceuticals Corporation | $51.72 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $46.98 | 2019-2022 | |
| Allergan, INC. | $28.02 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $27.94 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $27.73 | 2020-2021 | |
| Coopervision INC. | $25.65 | 2022 | |
| Oyster Point Pharma, INC. | $19.72 | 2022 | |
| Lkc Technologies, INC. | $18.52 | 2025 | |
| Maculogix, INC. | $17.68 | 2019 | |
| Abbvie INC. | $16.62 | 2023 | Vuity, Lumigan, Alphagan P |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Deckard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.